Monami Thakur

391-420 (out of 1197)

Novartis Drug ACZ885 Cuts Steroid Use in 45% of Children with Arthritis

Following the Phase III analysis by Novartis Pharmaceuticals Corporation, it was found that around 45 percent of children with active systemic juvenile idiopathic arthritis (SJIA) were able to reduce their dependence on oral corticosteroids following the treatment with ACZ885 (canakinumab).

Pages